Research map: Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development

Back to the article

Papers in this map

  1. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma · Tony S.K. Mok · 2009 · 8328 citations · Cited by this paper
  2. Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab · 2026 · Related
  3. Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer · Jennifer S. Temel · 2010 · 7563 citations · Cited by this paper
  4. Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program · 2026 · Related
  5. The Will Rogers Phenomenon · Alvan R. Feinstein · 1985 · 1563 citations · Cited by this paper
  6. AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group · 2026 · Related
  7. Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review · Nicole M. Kuderer · 2007 · 730 citations · Cited by this paper
  8. Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up · 2026 · Related
  9. Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival · Kristine R. Broglio · 2009 · 492 citations · Cited by this paper
  10. Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor · 2026 · Related
  11. Costs of Drug Development and Research and Development Intensity in the US, 2000-2018 · Aylin Sertkaya · 2024 · 239 citations · Cited by this paper
  12. SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer · 2026 · Related
  13. Propensity Score Methods in Health Technology Assessment: Principles, Extended Applications, and Recent Advances · Mohammed Sanni Ali · 2019 · 214 citations · Cited by this paper
  14. Moderate Hypofractionation for Regional Node Irradiation Is Safe and Effective · 2026 · Related
  15. The Costs of Conducting Clinical Research · Ezekiel J. Emanuel · 2003 · 166 citations · Cited by this paper
  16. Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743 · 2026 · Related
  17. Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens · Mohammad I. Zia · 2005 · 157 citations · Cited by this paper
  18. Limiting Dexamethasone Exposure With Highly Emetogenic Chemotherapy Regimens: Is the Verdict In? · 2026 · Related
  19. External control arms in oncology: current use and future directions · Pallavi Shruti Mishra-Kalyani · 2022 · 138 citations · Cited by this paper
  20. The Use of External Controls in FDA Regulatory Decision Making · Mahta Jahanshahi · 2021 · 137 citations · Cited by this paper
  21. Real‐world evidence to support regulatory decision‐making for medicines: Considerations for external control arms · Mehmet Burcu · 2020 · 125 citations · Cited by this paper
  22. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review · Sarah M. Goring · 2019 · 101 citations · Cited by this paper
  23. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer · Daniel Brock Hewitt · 2020 · 97 citations · Cited by this paper
  24. Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose Computed Tomography Screening · Anil Vachani · 2022 · 77 citations · Cited by this paper
  25. Benefits of Participation in Clinical Trials: An Umbrella Review · Amira Bouzalmate-Hajjaj · 2022 · 71 citations · Cited by this paper
  26. When is crossover desirable in cancer drug trials and when is it problematic? · Alyson Haslam · 2018 · 65 citations · Cited by this paper
  27. Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success? · John K. Chan · 2008 · 60 citations · Cited by this paper
  28. Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practice · Dario de Biase · 2023 · 47 citations · Cited by this paper
  29. Real‐World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men · Albert L. Kraus · 2021 · 44 citations · Cited by this paper
  30. Antifungal Prophylaxis Associated With Decreased Induction Mortality Rates and Resources Utilized in Children With New-Onset Acute Myeloid Leukemia · Brian T. Fisher · 2013 · 24 citations · Cited by this paper
  31. Differential frequency in imaging‐based outcome measurement: Bias in real‐world oncology comparative‐effectiveness studies · Blythe J. S. Adamson · 2021 · 23 citations · Cited by this paper
  32. Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations · Katherine Tan · 2022 · 23 citations · Cited by this paper
  33. Exploring the Potential of External Control Arms created from Patient Level Data: A case study in non-small cell lung cancer · Xiang Yin · 2022 · 19 citations · Cited by this paper
  34. Externally Controlled Studies Using Real-World Data in Patients With Hematological Cancers · Sjoerd J. F. Hermans · 2024 · 15 citations · Cited by this paper
  35. Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival · Alfredo Addeo · 2019 · 13 citations · Cited by this paper
  36. Critical Aspects of a Sustainable Clinical Research Program in the Community-Based Oncology Practice · Jennifer Lynne Ersek · 2019 · 9 citations · Cited by this paper
  37. Clinical development of new drugs for adults and children with cancer, 2010-2020 · Andrea Arfè · 2023 · 9 citations · Cited by this paper
  38. Bridging the Gap in Cancer Clinical Trial Funding · Yara George Abdou · 2024 · 6 citations · Cited by this paper
  39. Expected vs observed effect sizes for survival endpoints in phase 3 oncology trials · Sophia J. Lamp · 2025 · 6 citations · Cited by this paper

Source: OpenAlex (CC0)